There is much we don't understand about the aging of the human body, but working with what we do know researchers continue to uncover potential new ways to slow down the process. Among them is a team of genetic scientists at the Salk Institute, which has developed a new therapy using the CRISPR/Cas9 tool that has greatly boosted the lifespan of rapidly aging mice.

The work carried out in the Salk Institute's Gene Expression Laboratory involved mice engineered with a very rare genetic condition known as Hutchinson-Gilford progeria syndrome, or simply progeria. Caused by a mutation in the LMNA gene, the condition affects one in four million babies worldwide and leads to rapid aging, with the average life expectancy for a child born with progeria around 13 years.

Progeria is not the only degenerative disease caused by a mutation in the LMNA gene, but it is one of the most severe. In a healthy subject, the gene codes for two proteins called lamin A and lamin C. In progeria patients, it instead produces a shorter, toxic version of lamin A called progerin, which builds up quickly with and accelerates the aging process.

"Both humans and mice harboring a mutation in the LMNA gene manifest prematurely aging characteristics, such as an increase in DNA damage, loss of epigenetic marks and loss of stem cell populations," Pradeep Reddy, author on the new paper, explains to New Atlas. "Importantly, most of these phenotypes resemble the ones normally observed during aging in the general population. For this reason, progeria syndrome models are widely used to understand the mechanisms driving the process of aging and also to test the newly developed interventions in a short period of time."

Pradeep Reddy (front left) was a member of a research team at the Salk Institute that has developed a promising anti-aging technology using the CRISPR gene-editing tool Salk Institue

Reddy and his colleagues sought to limit the buildup of progerin by targeting the LMNA gene in the mice to blanket its toxicity. To do this, they delivered the CRISPR/Cas9 gene editing tools using an adeno-associated virus (AAV), which carried them to the right place on the DNA in order to make a critical cut and prevent the lamin A and progerin proteins from functioning, without impacting lamin C.

The scientists watched on as the treated mice became stronger and more active after two months, exhibiting improved cardiovascular health. The treatment also appeared to delay common symptoms of progeria and old age: degenerating arterial blood vessels and bradycardia (an abnormally slow heart rate). Ultimately, the treatment restored the activity levels of the progeria-afflicted mouse models to those of normal, healthy mice and increased their life span by around 25 percent.

Two mice of the same age with progeria, with the mouse on the left receiving the newly developed gene therapy Salk Institue

Currently there is no cure for progeria, so this breakthrough could have significant implications for the effort to uncover new treatments. But because of its similarities in the molecular pathways associated with aging in the general population, the scientists are hopeful their work can be adapted to target the molecular drivers of aging in all humans. And in this regard, they've already got some ideas.

"Among the many molecular drivers of aging, abnormalities in the nuclear envelope of the cells are observed with age," Reddy tells us. "This is due to the accumulation of the toxic form of LMNA gene product. In such cases, our method can be used to permanently fix the problem by blocking the expression of the gene."

The research was published in the journal Nature Medicine, while the short video below provides an overview of the breakthrough.

Source: Salk Institute